Amendment and WAIVER AgreementAmendment and Waiver Agreement • February 9th, 2023 • SRAX, Inc. • Services-advertising agencies • New York
This AMENDMENT AND WAIVER AGREEMENT (the “Agreement”) dated as of February 2, 2023 is entered into by and between SRAX, Inc., a Delaware Corporation (the “Company”) and the entities identified on the signature pages hereto (each, a “Holder” and, collectively, the “Holders”).
BILL OF SALE AND ASSIGNMENT AND ASSUMPTION AGREEMENTBill of Sale and Assignment and Assumption Agreement • February 9th, 2023 • SRAX, Inc. • Services-advertising agencies • Delaware
THIS BILL OF SALE AND ASSIGNMENT AND ASSUMPTION AGREEMENT, dated as of February 3, 2023 (this “Agreement”), is entered into by and between SRAX, Inc., a Delaware corporation (the “Buyer”), and DNA Holdings, LLC, a limited liability company formed under the laws of the Commonwealth of Puerto Rico (the “Seller”).
ASSET PURCHASE AGREEMENT by and between SRAX, INC. and DNA HOLDINGS, LLC DATED AS OF FEBRUARY 3, 2023Asset Purchase Agreement • February 9th, 2023 • SRAX, Inc. • Services-advertising agencies • Delaware
ASSET PURCHASE AGREEMENT, dated as of February 3, 2023 (this “Agreement”), by and between SRAX, Inc., a Delaware corporation (the “Buyer”), and DNA Holdings, LLC, a limited liability company formed under the laws of the Commonwealth of Puerto Rico (the “Seller”). The Seller and the Buyer may sometimes be referred to herein individually as a “Party” and collectively as the “Parties”. Capitalized terms used but not otherwise defined herein have the meanings ascribed to such terms in Article 9.
Lock-Up Agreement February 3, 2023Lock-Up Agreement • February 9th, 2023 • SRAX, Inc. • Services-advertising agencies
On February 3, 2023 (the “Effective Date”), SRAX, Inc., a Delaware corporation (“SRAX”) entered into an Asset Purchase Agreement (the “APA”) with DNA Holdings, LLC, a limited liability company formed under the laws of the Commonwealth of Puerto Rico (“DNA”, together with SRAX, the “Parties”). In connection with the transactions contemplated by the Transaction Documents (as defined in the APA), DNA will receive shares of Buyer Common Stock and Buyer Preferred Stock (collectively, the “Buyer Securities”). Capitalized terms used but not otherwise defined herein shall have the respective meanings ascribed to such terms in the APA.
